FRA
ZBH icon

Front Row Advisors’s Zimmer Biomet ZBH Stock Holding History

Front Row Advisors’s Portfolio ZBH Stock Details ZBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21
Closed -$2K – 1030
2020
Q2 		$2K Hold
21
– – ﹤0.01% 887
2020
Q1 		$2K Sell
21
-21
-50% -$2.75K ﹤0.01% 861
2019
Q4 		$6K Buy
42
+8
+24% +$1.1K ﹤0.01% 594
2019
Q3 		$5K Buy
34
+10
+42% +$1.29K ﹤0.01% 627
2019
Q2 		$3K Buy
+24
New +$2.81K ﹤0.01% 782

Other funds holding ZBH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Front Row Advisors's ZBH Position: Q3 2020 in Review

Front Row Advisors sold out of Zimmer Biomet (ZBH) in Q3 2020, closing a stake of 21 shares — an estimated $2K sold.

Front Row Advisors first reported a position in ZBH in Q2 2019 and held it in 5 quarters. The position peaked at $6K in Q4 2019. 930 funds tracked by Wall St. Rank hold ZBH as of Q3 2020.

  • Front Row Advisors reported no remaining Zimmer Biomet position as of Q3 2020 after selling out during the quarter.
  • Front Row Advisors sold 21 Zimmer Biomet shares in Q3 2020, an estimated $2K.
  • Front Row Advisors first reported a position in Zimmer Biomet in Q2 2019 and held it in 5 quarters.
  • Front Row Advisors's Zimmer Biomet position peaked at $6K in Q4 2019.
  • 930 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.